England Rejects Funding For Kimmtrak, Onureg & Minjuvi But Says Yes To Idefirix, Evrenzo & Verzenios
Executive Summary
Immunocore’s advanced uveal melanoma drug, Kimmtrak, and Hansa’s Idefirix for increasing the chances of a successful kidney transplant are among the latest treatments that NICE has appraised regarding their cost-effectiveness.
You may also be interested in...
Improved Discount Helps Lilly Secure English Funding For Verzenios
Verzenios is now the second CDK4/6 inhibitor for advanced breast cancer that can be used routinely on England’s National Health Service in patients in a second-line setting.
Valneva Wins EU Nod For COVID-19 Vaccine
In contrast with the five COVID-19 vaccines that are approved in the EU under conditional marketing authorizations, the European Medicines Agency has recommended that Valneva’s vaccine receive a standard approval.
New EU Filings
Adagrasib, Mirati Therapeutics' treatment for patients with non-small cell lung cancer, is among the latest new medicines that have been submitted for review for potential pan-EU approval.